It inhibited the renewal of glioma stem cells (GSCs) by activating JNK/ERK signaling, while it suppressed the expansion of glioma cells by inactivating the Atk pathway [6, 7], which indicated that the mechanism of DMC-BH in different cell lines is also inconsistent. The gene discussed is BTK; the disease is central nervous system cancer.